Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:20:43.881Z.
Calculation as of: 2026-10-06T18:20:43.881Z.
Quote observation: 2026-10-06T18:03:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3f32b4356dd318fc5fc0a902c875af90b1a094ceb52f500a6b854293a5898a5a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Basel Medical Group Ltd Ordinary Shares
Market Cap
$5.03M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Basel Medical Group Ltd Ordinary Shares (BMGL) | $5.03M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.95M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.08M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.12M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.90M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.81M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.21M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.26M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
